Table 2.

Summary outcomes for patients receiving modafinil or placebo in the OSA studies

Study/Reference	Measure	Treatment	Mean at baseline	Mean at final visit	Mean (SD) change from baseline to final visit	P-valuea
4-week study/Pack et al 2001	MSLT sleep latency (min)	Modafinil 400 mg	7.4	8.6		<0.05
		Placebo	7.5	7.2
	ESS score	Modafinil 400 mg	14.2	9.6		<0.001
		Placebo	14.4	12.4
4-week study/Dinges and Weaver 2003	PVT number of lapses (msec)	Modafinil 400 mg			−0.814 (0.426)	0.112
		Placebo			0.346 (.550)
	PVT number of lapses transformed (msec)	Modafinil 400 mg			−0.532 (0.177b)	0.01
		Placebo			0.118 (0.171b)
	PVT median reaction time (msec)	Modafinil 400 mg			−10.343 (4.424b)	0.01
		Placebo			4.936 (4.777b)
12-week study/Black and Hirshkowitz 2005	MWT sleep latency (min)	Modafinil 200 mg			1.6	<0.0001c
		Modafinil 400 mg			1.5
		Placebo			−1.1
	ESS score	Modafinil 200 mg			−4.5	<0.0001c
		Modafinil 400 mg			−4.5
		Placebo			−1.8
	FOSQ total score	Modafinil 200 mg			1.92 (2.47)	0.001d
		Modafinil 400 mg			2.13 (2.61)
		Placebo			0.84 (1.89)
	FOSQ vigilance	Modafinil 200 mg			0.48 (0.67)	0.0007d
		Modafinil 400 mg			0.55 (0.59)
		Placebo			0.25 (0.54)
	FOSQ general productivity	Modafinil 200 mg			0.30 (0.45)	0.0006d
		Modafinil 400 mg			0.33 (0.49)
		Placebo			0.08 (0.40)
	FOSQ activity	Modafinil 200 mg			0.41 (0.59)	0.02d
		Modafinil 400 mg			0.45 (0.65)
		Placebo			0.20 (0.49)

^aFor the change from baseline for modafinil versus placebo.

^bSEM.

^cFor overall and pairwise comparisons of modafinil with placebo.

^dFor overall comparisons of modafinil with placebo.

Abbreviations: SD, standard deviation; OSA, obstructive sleep apnea; MSLT, Multiple Sleep Latency Test; ESS, Epworth Sleepiness Scale; PVT, Psychomotor Vigilance Task; MWT, Maintenance of Wakefulness Test; FOSQ, Functional Outcomes of Sleep Questionnaire.